Skip to main content
SpringerLink
Log in

Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Twenty-two advanced consecutive thyroid cancer patients with varying histologies were treated with the so called BAP regime which consisted of bleomycin (B) 30 mg a day for three days, adriamycin (A) 60 mg/m2 iv in day 5, and cisplatinum (P) 60 mg/m2 iv in day 5. Patients with progressive, symptomatic recurrent or disseminated disease unresponsive to hormonal and/or isotopic treatment were eligible. Nine patients had an objective response: two long-lasting complete and seven partial responses were observed out of 21 evaluable patients. Stable disease was observed in four additional patients. The median duration of response was 12 months (range, 6–29). The total series experienced a median survival of 11 months (range, 1 to 57), with 2 patients actually disease free. Several histologic types of thyroid carcinoma responded, but the best responses were observed in medullary and anaplastic giant-cell carcinomas. Toxicity was reversible in all but one patient. Of the patients failing on BAP chemotherapy three responded to a four drug second line combination containing vincristine, fluorouracil, BCNU and methotrexate. BAP regime can achieve reasonable palliation, and probably increases survival, in poor-prognosis thyroid cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ibanez M.I., Russel W.O., Albares-Saavedra J., Lampertico P., White E.C., Lee Clark R. Thyroid carcinoma-biologic behavior and mortality. Cancer 19: 1039, 1966.

    Article  PubMed  CAS  Google Scholar 

  2. Beanfie J.M., Brown C.L., Doniach I., Richardson J.E. Primary malignant tumors of the thyroid: the relationship between histological classification and clinical behavior. Br. J. Surg. 63: 173, 1981.

    Google Scholar 

  3. Taylor S. Thyroid carcinoma and its treatment. Postgrad. Med. J. 44: 404, 1968.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  4. De Besi P., Fiorentino M.V. Importance of thyroxine in suppressing secretion of thyroid stimulating hormones (letter). Br. Med. J. 284: 1705, 1982.

    Article  Google Scholar 

  5. Schumacher P., Metz R., Bey P., Chesnean A.M. Anaplastic Carcinoma of the Thyroid Gland. Eur. J. Cancer Clin. Oncol. 13: 381, 1977.

    Google Scholar 

  6. Hainan K.E. The non-surgical treatment of thyroid cancer. Br. J. Surg. 62: 769, 1975.

    Article  Google Scholar 

  7. Higby D.J., Wallace H.J. Jr., Albert D.J., Holland J.F. Diamminedichloroplatinum; A phase I study showing responses in testicular and other tumors. Cancer 33: 1219, 1974.

    Article  PubMed  CAS  Google Scholar 

  8. Sako K., Razack M.S., Kalnins I. Chemotherapy for advanced and recurrent squamous cell carcinoma of head and neck with high and low dose cis-diamminedichloroplatinum. Am. J. Surg. 136: 529, 1978.

    Article  PubMed  CAS  Google Scholar 

  9. Spanos G.A., Wolk D., Desner M.R., Khan A., Platt N., Khafif R.A., Cortes E.P. Preoperative chemotherapy for giant cell carcinoma of the thyroid. Cancer 50: 2252, 1982.

    Article  PubMed  CAS  Google Scholar 

  10. Omura G.A., Roberts G.A. Combination therapy of solid tumors using 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU), Vincristine, Methotrexate, and 5-Fluorouracil. Cancer 31: 1374, 1973.

    Article  PubMed  CAS  Google Scholar 

  11. Gralla R.J., Itri L.M., Pisko S.E., Squillante A.E., Kelsen D.P., Braun D.W., Bordin L.A., Braun T.J., Young C.W. Antiemetic efficacy of high dose methoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 305: 905, 1981.

    Article  PubMed  CAS  Google Scholar 

  12. Hayat M. Status of chemotherapy for thyroid carcinomas. Ann. Radiol. 20: 807, 1977.

    Google Scholar 

  13. Poster D.S., Bruno S., Penta J., Pina K., Catone R. Current status of chemotherapy in the treatment of advanced carcinoma of the thyroid gland. Cancer Clin. Trials 4: 301, 1981.

    PubMed  CAS  Google Scholar 

  14. Di Marco A., Gaetani M., Scarpinato B. Adriamycin (NSC-123, 217): a new antibiotic with antitumor activity. Cancer Chemother. Rep. 53: 33, 1969.

    PubMed  Google Scholar 

  15. Gottlieb J.A., Hill C.S., Ibanez M.L., Clark R.L. Chemotherapy of thyroid cancer. An evaluation experience with 37 patients. Cancer 30: 848, 1972.

    Article  PubMed  CAS  Google Scholar 

  16. Gottlieb J.A., Stratton Hill C. Chemotherapy of thyroid cancer with adriamycin: Experience with 30 patients. N. Engl. Med. 290: 193, 1974.

    Article  CAS  Google Scholar 

  17. Fiorentino M., Grigoletto E., Guglielmi M. Cancer indifferencie du corps Thyroide. Guerison par adriamycine. Nouv. Press Med. 4: 2884, 1975.

    CAS  Google Scholar 

  18. Harada T., Nishikawa Y., Suzuki T., Ito K., Baba S. Bleomycin treatment for cancer of the Thyroid. Am. J. Surg. 122: 53, 1971.

    Article  PubMed  CAS  Google Scholar 

  19. Hainan K.E., Bleehan N.M., Brewin T.B., Deeley T.J., Harrison D.F.N., Howland p., Kunkler P.W., Ritchie G.L., Wiltshaw E., Todd I.D.H. Early clinical experience with bleomycin in the United Kingdom in a series of 105 patients. Br. Med. J. 4: 635, 1972.

    Article  Google Scholar 

  20. Droz J.P., Morardet N., Charbord P., Maraninchi D., Hayat M., Parmentier C. Chemotherapy of differentiated thyroid carcinomas. Ann. Radiol. 20: 814, 1977.

    PubMed  CAS  Google Scholar 

  21. Blomgren H., Edsmyr F., Strender L.E. Effect of peplomycin on peripheral lymphocytes. Acta Radiol. Oncol. 20: 113, 1981.

    Article  PubMed  CAS  Google Scholar 

  22. Panettiere F., Coltman C.A. Phase I experience with emetine hydrochloride (nsc 33669) as an antitumor agent. Cancer 27: 835, 1971.

    Article  PubMed  CAS  Google Scholar 

  23. Juret P., Tanguy A., Girard A., Le Talaer J.Y., Abbatucci J.S., Dat-Juong, Le Pecq J.B., Paoletti C. Hydroxy9-methyl 2-ellipticinum acetate (nsc 264-137). Toxicologic study and therapeutic effect in 100 cancers. Nouv. Press Med. 8: 1495, 1979.

    CAS  Google Scholar 

  24. Benker G., Dabag S., Reinwein D. Chemotherapy of thyroid carcinoma. Benefits and side effects. In: M. Andreoli, F. Monaco, J. Robbins (Eds.), Advances in Thyroid Neoplasia. Field Educational Italia, Rome 1981, p. 263.

    Google Scholar 

  25. Leeper R.D., Shimaoka K. Treatment of metastatic thyroid cancer. Clin. Endocrinol. Metab. 9: 383, 1980.

    Article  PubMed  CAS  Google Scholar 

  26. Benker G., Hackenberg K., Hoff H.G., Seeber S., Ebke J., Windek R., Reinwein D. Zytostatische Kombinationsbehandlung metastasierender schilddrusenkarzinome mit doxorubicin und bleomycin. Dtsch. Med. Wschr. 102: 1908, 1977.

    Article  PubMed  CAS  Google Scholar 

  27. Sokal M., Harmer C.L. Chemotherapy for anaplastic carcinoma of the thyroid. Clin. Oncol. 4: 3, 1978.

    PubMed  CAS  Google Scholar 

  28. Durie B.G.M., Hellman D., Woolfenden J.M., O’Mara R.O., Kartchner M., Salmon S.E. High risk thyroid cancer. Prolonged survival with early multimodality therapy. Cancer Clin. Trials 4: 67, 1981.

    PubMed  CAS  Google Scholar 

  29. Bukowski R.M., Brown L., Weick J.K., Groppe C.W., Purvis J. Combination chemotherapy of metastatic thyroid cancer. Phase II study. Am. J. Clin. Oncol. 6: 579, 1983.

    Article  PubMed  CAS  Google Scholar 

  30. Droz J.P., Charbord P., Rougier Ph., Parmentier Cl. Failure of chemotherapy in thyroid cancers. Bull. Cancer (Paris) 68: 350, 1981.

    CAS  Google Scholar 

  31. Shimaoka K., Schoenfeld D.A., Lerner H., De Conti R.C., ECOG. A randomized trial of adriamycin versus adriamycin plus cis-diammine-dichloroplatinum in patients with thyroid carcinoma. Proc. Am. Soc. Clin. Oncol. 2: 168, 1983.

    Google Scholar 

  32. Williams S.D., Birch R., Einhorn L.H. Phase II evaluation of Doxorubicin Plus Cisplatin in Advanced Thyroid cancer: A Southeastern Cancer Study Group Trial. Cancer Treat. Rep. 70: 405, 1986.

    PubMed  CAS  Google Scholar 

  33. Hoskin P.L.J. and Harmer C.L. Chemotherapy for thyroid cancer. Radiotherapy and Oncology 10: 187, 1987.

    Article  PubMed  CAS  Google Scholar 

  34. Sikic B.I., Collins J.M., Mimnaugh E.G. Improved therapeutic index of Bleomycin when administered by continuous infusion in mice. Cancer Treat. Rep. 62: 2011, 1978.

    PubMed  CAS  Google Scholar 

  35. Fomasiero A., Daniele O., Paccagnella A., Fosser V., Cartei G., Ferrazzi E., Fiorentino M. Toxicity from Continuous Infusion of High Doses of Bleomycin. Tumori, 66: 607, 1980.

    Google Scholar 

  36. Vogl S.E., Zaravinos T., Kaplan B.H. Toxicity of cis-diamminedichloroplatinum II given in a two-hour outpatient regimens of diuresis and hydration. Cancer 45: 11, 1980.

    Article  PubMed  CAS  Google Scholar 

  37. Simioni N., Busnardo B., Girelli M.E., Zorat P.L., Pelizzo M.R., Eccher C., De Besi P., Casara D. Medullary thyroid Carcinoma: Clinical-Epidemiological Study of 62 Patients. J. Endocrinol Invest. (Suppl. 1): 217, 1984.

  38. Busnardo B., Girelli M.E., Simioni N., Zorat P.L., Pelizzo M.R., Eccher C., De Besi P., Fassina A., Casara D. Diagnosis and therapy of medullary carcinomas: survey on 74 patients. In: Jaffiol C., Milhaud G. (Eds).), Thyroid Cancer. Elsevier Science Publ., Amsterdam, 1985, p. 307.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisione Oncologia Medica, U.L.S.S.N. 21, 35100, Padova, Italy

    Pietro De Besi M.D., S. Toso & M. V. Fiorentino

  2. Istituto Semeiotica Medica, Padova, Italy

    B. Busnardo, M. E. Girelli, D. Nacamulli & N. Simioni

  3. Divisione Radioterapia, U.L.S.S.N. 21, Padova, Italy

    D. Casara & P. Zorat

Authors
  1. Pietro De Besi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Busnardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Toso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. E. Girelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Nacamulli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Simioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Casara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. Zorat
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. V. Fiorentino
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported, in part, by a grant of the Regione del Veneto, Ricerca finalizzata su Tumori della Tiroide.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Besi, P., Busnardo, B., Toso, S. et al. Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 14, 475–480 (1991). https://doi.org/10.1007/BF03346846

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346846

Key-words

Search

Navigation